Bristol-Myers Squibb (NYSE:BMY) Shares Sold by White Pine Capital LLC

White Pine Capital LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 21.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 23,345 shares of the biopharmaceutical company’s stock after selling 6,322 shares during the quarter. White Pine Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,198,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BMY. Addison Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 23.4% in the fourth quarter. Addison Advisors LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $198,000 after acquiring an additional 731 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $274,000. Fulton Breakefield Broenniman LLC raised its stake in shares of Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 209 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $650,000. Finally, Citizens Financial Group Inc. RI raised its stake in shares of Bristol-Myers Squibb by 6.3% in the fourth quarter. Citizens Financial Group Inc. RI now owns 27,693 shares of the biopharmaceutical company’s stock valued at $1,421,000 after acquiring an additional 1,646 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Barclays cut their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Finally, Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded up $0.15 during midday trading on Friday, reaching $44.85. 21,281,927 shares of the company were exchanged, compared to its average volume of 12,141,314. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 1 year low of $44.34 and a 1 year high of $69.10. The stock has a fifty day simple moving average of $51.03 and a 200 day simple moving average of $51.18. The stock has a market cap of $90.90 billion, a P/E ratio of -14.47, a PEG ratio of 16.25 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 50.04% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the company posted $2.05 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. On average, research analysts forecast that Bristol-Myers Squibb will post 0.55 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.35%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.